EU News
Printable version

Coronavirus: Commission completes vaccines portfolio following talks with a sixth manufacturer

The European Commission yesterday concluded exploratory talks with BioNTech-Pfizer to purchase a potential vaccine against COVID-19. BioNTech-Pfizer is the sixth company with which the Commission has concluded talks, following Sanofi-GSK on 31 July, Johnson & Johnson on 13 August, CureVac on 18 August and Moderna on 24 August. The first contract, signed with AstraZeneca, entered into force on 27 August.

The envisaged contract with BioNTech-Pfizer would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to European countries. It is anticipated that the Commission will have a contractual framework in place for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to purchase up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.

Ursula von der Leyen, President of the European Commission, yesterday said:

“I am happy to announce that we have concluded talks with BioNTech-Pfizer for an initial purchase of 200 million doses of future coronavirus vaccines. This is the 6th pharma company with which we have concluded talks or signed an agreement for potential vaccines, in record time. Our chances to develop and deploy a safe and effective vaccine have never been higher, both for Europeans here at home, or for the rest of the world. To defeat coronavirus anywhere, we need to defeat it everywhere.”

Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:

“Today's final talks with BioNTech-Pfizer is yet another important step in our efforts to build a sound and diverse portfolio of vaccine candidates. This was the objective of our EU Vaccine Strategy, and we are delivering on it. We are optimistic that among these candidates there will be a safe and effective vaccine against COVID-19 to help us defeat this pandemic.”

BioNTech is a German company working with US-based Pfizer to develop a new vaccine based on messenger RNA (mRNA). mRNA plays a fundamental role in human biology, transferring the instructions which direct cells in the body to make proteins to prevent or fight disease.

The exploratory talks concluded yesterday are intended to result in an Advance Purchase Agreement to be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles and produced by different companies.

Click here for the full press release


Original article link:

Share this article

Latest News from
EU News

Giving the elderly a voice in Parliament: An interview with Rachael Maskell MP